Skip to main content

Table 3 Antiviral activities of the title compounds against TMV in vivo at 500 μg/mL

From: Synthesis and biological activity of myricetin derivatives containing 1,3,4-thiadiazole scaffold

Compd.

Curative activity (%)

Protection activity (%)

Compd.

Curative activity (%)

Protection activity (%)

2

18.2 ± 7.3

21.5 ± 9.1

3j

28.7 ± 3.8

39.4 ± 3.1

3a

46.7 ± 5.2

50.3 ± 9.3

3k

28.0 ± 8.6

33.0 ± 7.5

3b

53.8 ± 9.0

54.1 ± 9.4

3l

33.9 ± 9.4

34.2 ± 5.4

3c

37.0 ± 9.1

58.4 ± 1.0

3m

57.1 ± 9.6

56.7 ± 8.2

3d

59.8 ± 9.2

54.3 ± 9.0

3n

48.4 ± 5.9

42.1 ± 7.1

3e

28.7 ± 8.3

35.4 ± 5.1

3o

50.8 ± 3.6

47.3 ± 2.9

3f

68.4 ± 7.4

54.4 ± 7.7

3p

34.6 ± 5.4

36.5 ± 1.6

3g

36.4 ± 3.8

38.6 ± 7.7

Myricetin a

28.8 ± 6.7

34.4 ± 7.2

3 h

44.8 ± 9.4

45.2 ± 1.5

Ningnanmycin a

51.8 ± 4.3

58.3 ± 2.9

3i

66.8 ± 9.8

60.8 ± 8.3

   
  1. Average of three replicates
  2. aNingnanmycin and myricetin were used for comparison of antiviral activity